According to a report, 16 new GLP-1-based weight loss drugs could be launched on the market by 2029 (NYSE:NVO)
Sep. 10, 2024, 6:56 pm Eastern TimeNovo Nordisk A/S (NVO) shares, LLY sharesAMGN, JNJ, RHHBYPFE, MRK, AZN, VKTX, GPCRBy: Val ...
Tag: NYSENVO
Novo Nordisk's Wegovy improves kidney health in patients with obesity (NYSE:NVO)
hapabapa/iStock Editorial via Getty Images Novo Nordisk's (NVO) anti-obesity therapy Wegovy reduced kidney-related adverse events by 22% in overweight and ...
Novo Nordisk, J&J Lead R&D at Big Pharma: Report (NYSE:NVO)
Andrii Yalanskyi Weight loss drug maker Novo Nordisk (NVO) and American healthcare giant Johnson & Johnson (New York Stock Exchange:JNJ) ...
Recommended.
